Leo Ehrlich comments on Cellceutix Corporation's breakthroughs with their ground-breaking compound KM-391 for the treatment of autism.
Sunday, March 28, 2010
Microcap Pipe Dreams or Previews in Reality?
Microcap Pipe Dreams or Previews in Reality?
Today’s investment world is clad with people of all different styles, but they all have one thing in common; a desire for profits. It doesn’t matter if you are a seasoned, multi-millionaire day trading shares of Berkshire Hathaway or the newest investor looking to start with five hundred dollars, the individuals do not enter into this aspect of finance with the goal of losing money. One of the most common phrases asked of anyone who makes any mention of being involved in the stock market is known globally and it goes a little something like this: “Got any hot tips?” The big boys of the macro cap markets and blue chip companies tend to keep a very tight lip for obvious reasons with miniscule amounts of information shared with everyday citizens. So where do many people look to find the next big thing? Many look to the microcap world to discover the “diamond in the rough”, the “hidden gem” or “the next Microsoft.” You can take your pick of any number of phrased given to describe a small, developmental company that is sliding under everyone’s radar while making big strides in their chosen industry. In the world of Over The Counter Bulletin Board (OTCBB) stocks, there is much speculation and rumors that are passed daily through one “hot tip” after another, so finding the companies worthy of your attention is indeed a challenge. Which companies are truly previews in reality as they research, develop and market their products and not just the vision of a dreamer?
Well, I have to believe that a person must start with some basic facts to increase their odds of success. I tell people to think about what they would look for if they were starting a company of their own. Would they want to enter into an industry with billions of dollars available for revenue potential? How about management? They must also consider their product. Is it unique, but something the majority of the world would desire? In order for a company to be strong and have a serious shot at longevity and growth potential, these are a few of the important factors that must be accounted for. When you find a company that answers these questions with solid answers, you have quite possibly gotten a glimpse of a preview in reality.
Cellceutix Corporation (OTCBB: CTIX), a developmental biotechnology company based in Beverly, MA is a company that has answered the required questions and passed all initial tests with flying colors. For management, Cellceutix was co-founded by a 26-year veteran of Pfizer, Inc., Mr. George Evans. Mr. Evans was General Counsel of Pfizer's worldwide prescription drug unit (accounting for about 96% of Pfizer’s revenues) and integral in the development and marketing of many of Pfizer’s pharmaceutical products before leaving to start Cellceutix with Dr. Krishna Menon. Dr. Menon’s list of biotechnology accolades throughout his almost 40 years in the field of research is impressive, to say the least, including being a President’s Recognition Award recipient while at Eli Lilly. With an extensive background in oncology research, Dr. Menon has been a lead researcher in several drugs that have gone on to produce billions of dollars in revenues for their respective companies.
As far as products, Cellceutix owns the rights to 8 different compounds that they are developing to treat a variety of major diseases in their own, innovative manners. Their flagship product, Kevetrin, has been shown with animal subjects to be effective in the treatment of cancer in subjects that have proven to be resistant to standard, proven cancer treatments on the market today. Cellceutix has already completed its pre-IND meeting with the FDA and is in the process of filing an IND for Phase I studies for Kevetrin. Tomorrow, per the Cellceutix website (www.cellceutix.com), a press release will be issued detailing the successes that they are having with another major compound in their pipeline, KM-391 in the treatment of autism. KM-391 is completely unique in that it merely doesn’t treat the behavior that results from autism; it is being developed to treat the disease at its root core.
The final piece of any successful company is responsible finances. Mr. Leo Ehrlich, CPA, handles this aspect of the business for Cellceutix. With a BBA from Bernard Baruch College of the City University of New York and over 25 years experience at a variety of upper-level management positions with several companies, Mr. Ehrlich has been with Cellceutix since its inception and more than adequately fills this crucial position.
Based on the requirements for getting a glimpse of reality, rather than a microcap pipe dream, Cellceutix is certainly a company worth keeping an eye and as this company is flying under the radar, but stands a great chance and making a large impact on a multi-billion dollar industry.
From a technical standpoint, CTIX still trades at a very low average daily volume. This is not without cause, however. Cellceutix is very “low key” about publicity for starters. The CTIX share structure does not have a very large float with only approximately 40 million free-trading shares out of the 92 million currently issued and outstanding. The float is held almost exclusively by a tight group of investors that are very optimistic of the future of Cellceutix (per Mr. Ehrlich). CTIX has been in a channel closing between .30 and .50 on low volume for about 5 months at this point, but I would suspect it may be seeing some more trading as their products keep working their way through the pipeline.
Today’s investment world is clad with people of all different styles, but they all have one thing in common; a desire for profits. It doesn’t matter if you are a seasoned, multi-millionaire day trading shares of Berkshire Hathaway or the newest investor looking to start with five hundred dollars, the individuals do not enter into this aspect of finance with the goal of losing money. One of the most common phrases asked of anyone who makes any mention of being involved in the stock market is known globally and it goes a little something like this: “Got any hot tips?” The big boys of the macro cap markets and blue chip companies tend to keep a very tight lip for obvious reasons with miniscule amounts of information shared with everyday citizens. So where do many people look to find the next big thing? Many look to the microcap world to discover the “diamond in the rough”, the “hidden gem” or “the next Microsoft.” You can take your pick of any number of phrased given to describe a small, developmental company that is sliding under everyone’s radar while making big strides in their chosen industry. In the world of Over The Counter Bulletin Board (OTCBB) stocks, there is much speculation and rumors that are passed daily through one “hot tip” after another, so finding the companies worthy of your attention is indeed a challenge. Which companies are truly previews in reality as they research, develop and market their products and not just the vision of a dreamer?
Well, I have to believe that a person must start with some basic facts to increase their odds of success. I tell people to think about what they would look for if they were starting a company of their own. Would they want to enter into an industry with billions of dollars available for revenue potential? How about management? They must also consider their product. Is it unique, but something the majority of the world would desire? In order for a company to be strong and have a serious shot at longevity and growth potential, these are a few of the important factors that must be accounted for. When you find a company that answers these questions with solid answers, you have quite possibly gotten a glimpse of a preview in reality.
Cellceutix Corporation (OTCBB: CTIX), a developmental biotechnology company based in Beverly, MA is a company that has answered the required questions and passed all initial tests with flying colors. For management, Cellceutix was co-founded by a 26-year veteran of Pfizer, Inc., Mr. George Evans. Mr. Evans was General Counsel of Pfizer's worldwide prescription drug unit (accounting for about 96% of Pfizer’s revenues) and integral in the development and marketing of many of Pfizer’s pharmaceutical products before leaving to start Cellceutix with Dr. Krishna Menon. Dr. Menon’s list of biotechnology accolades throughout his almost 40 years in the field of research is impressive, to say the least, including being a President’s Recognition Award recipient while at Eli Lilly. With an extensive background in oncology research, Dr. Menon has been a lead researcher in several drugs that have gone on to produce billions of dollars in revenues for their respective companies.
As far as products, Cellceutix owns the rights to 8 different compounds that they are developing to treat a variety of major diseases in their own, innovative manners. Their flagship product, Kevetrin, has been shown with animal subjects to be effective in the treatment of cancer in subjects that have proven to be resistant to standard, proven cancer treatments on the market today. Cellceutix has already completed its pre-IND meeting with the FDA and is in the process of filing an IND for Phase I studies for Kevetrin. Tomorrow, per the Cellceutix website (www.cellceutix.com), a press release will be issued detailing the successes that they are having with another major compound in their pipeline, KM-391 in the treatment of autism. KM-391 is completely unique in that it merely doesn’t treat the behavior that results from autism; it is being developed to treat the disease at its root core.
The final piece of any successful company is responsible finances. Mr. Leo Ehrlich, CPA, handles this aspect of the business for Cellceutix. With a BBA from Bernard Baruch College of the City University of New York and over 25 years experience at a variety of upper-level management positions with several companies, Mr. Ehrlich has been with Cellceutix since its inception and more than adequately fills this crucial position.
Based on the requirements for getting a glimpse of reality, rather than a microcap pipe dream, Cellceutix is certainly a company worth keeping an eye and as this company is flying under the radar, but stands a great chance and making a large impact on a multi-billion dollar industry.
From a technical standpoint, CTIX still trades at a very low average daily volume. This is not without cause, however. Cellceutix is very “low key” about publicity for starters. The CTIX share structure does not have a very large float with only approximately 40 million free-trading shares out of the 92 million currently issued and outstanding. The float is held almost exclusively by a tight group of investors that are very optimistic of the future of Cellceutix (per Mr. Ehrlich). CTIX has been in a channel closing between .30 and .50 on low volume for about 5 months at this point, but I would suspect it may be seeing some more trading as their products keep working their way through the pipeline.
Cellceutix Corporation: Breaking Down the Autism Barrier
Cellceutix Corporation: Breaking Down the Autism Barrier
“Autism”. The mere word is scary to most every parent. There are no known drugs for the treatment of autism. In fact, there are few, if any, products on the market that attempt to stop autism or counter-effect what is happening in the brain of the person with the disease. Autism spectrum disorders have a wide array of behaviors that result from it and the drugs that are prescribed are meant to deal with those symptoms, not the disease itself. Specific examples of the symptoms can include, but are not limited to:
• Bi-polar disorders
• Anxiety (or depression)
• Obsessive-compulsive disorder
• Hyperactivity
• Attention deficit
• Behavioral issues
• Seizures
There are many drugs that treat these symptoms including Prozac, Wellbutrin, Ritalin, haloperidol and Risperdone, which is still relatively new and without long-term studies being concluded for side effects. Regardless of which symptom these pharmaceuticals treat, they all have one thing in common; they only treat the symptom, not the underlying cause.
On Monday, March 29, 2010, you will be able to read about a company that is attempting to solve this long-time problem. Cellceutix Corporation is seeing positive results in the studies of their compound KM-391 that will be issued in a press release on that day.
To quote the Cellceutix website: “Preliminary testing of KM-391 in mice revealed that the test animals showed a significant increase in serotonin uptake compared to controls, with no apparent side-effects in the long-term administration of KM 391 in mice. The equalization of serotonin uptake is considered by many researchers as an important development in the treatment of autism spectrum disorders.”
The Cellceutix research team, headed by Chief Scientific Officer, Dr. Krishna Menon, has seen their small molecule have a direct impact on neonatal serotonin depletion and the plasticity of the brain in Wistar rat pups used in their experiments. Using three groups in their studies, the team replicated some of the leading features observed in autism in the rat pups at birth and then proceeded to conduct the studies on those features with treatment of KM-391. The results have been extremely positive. Cellceutix Corporation will be continuing to move forward with patents and eventual clinical testing of this possible solution to the root causes of autism.
Cellceutix Corporation, based in Waverly MA, is a publicly traded, developmental biotechnology company on the OTC Bulletin Board trading under the ticker CTIX. Cellceutix was co-founded in 2007 by a 26-year veteran of Pfizer, Inc., Mr. George Evans. Mr. Evans was General Counsel of Pfizer's worldwide prescription drug unit and integral in the development and marketing of many of Pfizer’s pharmaceutical products before leaving to start Cellceutix with Dr. Krishna Menon. Dr. Menon’s list of biotechnology accolades throughout his almost 40 years in the field of research is impressive, to say the least, including being a President’s Recognition Award recipient while at Eli Lilly. With an extensive background in oncology research, Dr. Menon has been a lead researcher in several drugs that have gone on to produce billions of dollars in revenues for their respective companies.
Cellceutix owns the rights to 8 different compounds that they are developing to treat a variety of major diseases in their own, innovative manners. Their flagship product, Kevetrin, has been shown with animal subjects to be effective in the treatment of cancer in subjects that have proven to be resistant to standard, proven cancer treatments on the market today. Cellceutix is in the process of aligning Phase I studies and patenting processes for Kevetrin.
“Autism”. The mere word is scary to most every parent. There are no known drugs for the treatment of autism. In fact, there are few, if any, products on the market that attempt to stop autism or counter-effect what is happening in the brain of the person with the disease. Autism spectrum disorders have a wide array of behaviors that result from it and the drugs that are prescribed are meant to deal with those symptoms, not the disease itself. Specific examples of the symptoms can include, but are not limited to:
• Bi-polar disorders
• Anxiety (or depression)
• Obsessive-compulsive disorder
• Hyperactivity
• Attention deficit
• Behavioral issues
• Seizures
There are many drugs that treat these symptoms including Prozac, Wellbutrin, Ritalin, haloperidol and Risperdone, which is still relatively new and without long-term studies being concluded for side effects. Regardless of which symptom these pharmaceuticals treat, they all have one thing in common; they only treat the symptom, not the underlying cause.
On Monday, March 29, 2010, you will be able to read about a company that is attempting to solve this long-time problem. Cellceutix Corporation is seeing positive results in the studies of their compound KM-391 that will be issued in a press release on that day.
To quote the Cellceutix website: “Preliminary testing of KM-391 in mice revealed that the test animals showed a significant increase in serotonin uptake compared to controls, with no apparent side-effects in the long-term administration of KM 391 in mice. The equalization of serotonin uptake is considered by many researchers as an important development in the treatment of autism spectrum disorders.”
The Cellceutix research team, headed by Chief Scientific Officer, Dr. Krishna Menon, has seen their small molecule have a direct impact on neonatal serotonin depletion and the plasticity of the brain in Wistar rat pups used in their experiments. Using three groups in their studies, the team replicated some of the leading features observed in autism in the rat pups at birth and then proceeded to conduct the studies on those features with treatment of KM-391. The results have been extremely positive. Cellceutix Corporation will be continuing to move forward with patents and eventual clinical testing of this possible solution to the root causes of autism.
Cellceutix Corporation, based in Waverly MA, is a publicly traded, developmental biotechnology company on the OTC Bulletin Board trading under the ticker CTIX. Cellceutix was co-founded in 2007 by a 26-year veteran of Pfizer, Inc., Mr. George Evans. Mr. Evans was General Counsel of Pfizer's worldwide prescription drug unit and integral in the development and marketing of many of Pfizer’s pharmaceutical products before leaving to start Cellceutix with Dr. Krishna Menon. Dr. Menon’s list of biotechnology accolades throughout his almost 40 years in the field of research is impressive, to say the least, including being a President’s Recognition Award recipient while at Eli Lilly. With an extensive background in oncology research, Dr. Menon has been a lead researcher in several drugs that have gone on to produce billions of dollars in revenues for their respective companies.
Cellceutix owns the rights to 8 different compounds that they are developing to treat a variety of major diseases in their own, innovative manners. Their flagship product, Kevetrin, has been shown with animal subjects to be effective in the treatment of cancer in subjects that have proven to be resistant to standard, proven cancer treatments on the market today. Cellceutix is in the process of aligning Phase I studies and patenting processes for Kevetrin.
Tuesday, March 23, 2010
Consorteum Holdings, Inc (OTCBB: CSRH)
QualityStocks.net has asked me to do some videos for them. I am proud to work with a website of their caliber. My annotated video chart on CSRH: http://www.youtube.com/user/QualityStocks
Wednesday, March 17, 2010
CPF - Central Pacific Financial - Another Winner!
At OTC Showcase, we work with pincherplays.com on their forums to make trades daily. CPF was another solid winner yesterday for us and it is still moving up nicely today after busting through resistance yesterday.
You can also view this video in High Def on YouTube here. Join us at PincherPlays and OTC Showcase to start reaping gains daily just like us!!
You can also view this video in High Def on YouTube here. Join us at PincherPlays and OTC Showcase to start reaping gains daily just like us!!
Friday, March 12, 2010
Eternal Image Letter to Shareholders
Eternal Image has issued a letter to their shareholders announcing the good news of Emerald Assets "locking up" shares. What a great vote of confidence!
Letter to Shareholders
"March 12, 2010
Shareholder Bulletin
Dear Shareholders, In addition to the share retirement that was announced on February 19, Management would like to inform everyone that effective immediately, Emerald Asset Advisors, LLC has agreed to a lock-up of their 40+ million shares of Eternal Image stock. They are taking this step to show their commitment to being long-term holder and that they too share our commitment to seeing Eternal Image reach profitability and a higher pps. The shares are in certificate form and will be held in escrow with our corporate SEC counsel for 6-months effective today. Thank you all for your continued support."
To view more information on Eternal Image, Inc. join us at http://www.otcshowcase.com/
Letter to Shareholders
"March 12, 2010
Shareholder Bulletin
Dear Shareholders, In addition to the share retirement that was announced on February 19, Management would like to inform everyone that effective immediately, Emerald Asset Advisors, LLC has agreed to a lock-up of their 40+ million shares of Eternal Image stock. They are taking this step to show their commitment to being long-term holder and that they too share our commitment to seeing Eternal Image reach profitability and a higher pps. The shares are in certificate form and will be held in escrow with our corporate SEC counsel for 6-months effective today. Thank you all for your continued support."
To view more information on Eternal Image, Inc. join us at http://www.otcshowcase.com/
Wednesday, March 10, 2010
ETNL Names President of Upcoming Ancillary Division
Gift-Industry Leader Joins Eternal Image
Frank Colapinto to Head New Division
Press Release Source: Eternal Image, Inc. On Wednesday March 10, 2010, 9:15 am
FARMINGTON HILLS, Mich., March 10, 2010 (GLOBE NEWSWIRE) — Eternal Image, Inc. (the “Company”) (OTCBB:ETNL – News), a public company engaged in the design, manufacturing and marketing of officially licensed funerary products such as caskets, urns, monuments and vaults, today announced that it has successfully retained the services of Mr. Frank Colapinto. He will assume the position of President of the Company’s forthcoming new division as previously reported in a press release dated March 4, 2010.
“Eternal Image could not have found a more qualified individual to spearhead our new division that will handle the manufacturing and marketing of our ancillary products,” said Nick Popravsky, VP Sales & Marketing, Eternal Image. “Frank has decades of experience in the gift industry and his manufacturing and sales contacts around the world will be a tremendous asset to our Company.”
Frank Colapinto is a past Senior Vice President and President of two major gift industry companies with sales in excess of $60 million. He has more than 35 years of global gift industry experience and has always been a fixture at most national gift product shows. His own personal sales averaged over $10 million per year, and his book of business includes 500 independent sales reps both nationally and worldwide.
“I am thrilled to be on board with Eternal Image, “said Frank Colapinto. “This Company has enormous potential for growth and I plan to develop the ancillary product division into a very profitable segment for the Company’s bottom line. Candles, register books, prayer cards and keepsakes–my plans for them all are global in scope and I will exponentially increase the availability of Eternal Image products to an international market.”
About Eternal Image
Eternal Image, incorporated in 2006, is headquartered in Farmington Hills, MI. The company is the first and only manufacturer and marketer of licensed brand image funerary products. Currently, the company offers urns and caskets that feature licensed images from Major League Baseball(TM), STAR TREK(R), Precious Moments(TM), the Vatican Observatory Foundation(R), and the Collegiate Licensing Company, as well as pet urns featuring the American Kennel Club(TM), and Cat Fanciers’(TM) Association. For more information about EI, visit www.eternalimage.net or call 1-888-6-CASKET.
SAFE HARBOR STATEMENT
Statements in this news release relating to plans, strategies, economic performance and trends, projections of results of specific activities or investments, and other statements that are not descriptions of historical facts may be forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1993 and Section 21E of the Securities Exchange Act of 1934.
Forward-looking information is inherently subject to risks and uncertainties, and actual results could differ materially from those currently anticipated due to a number of factors, which include but are not limited to risk factors inherent in doing business. Forward-looking statements may be identified by terms such as “may”, “will,” “should,” “could,” “expects,” “plans,” “intends,” “anticipates,” “believes,” “estimates,” “predicts,” “forecasts,” “potential” or “continue” or similar terms or the negative of these terms.
Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, levels of activity, performance or achievements. These forward-looking statements are based on information currently available to the Company and are subject to a number of risks, uncertainties, and other factors that could cause the Company’s actual results, performance, prospects, and opportunities to differ materially from those expressed in, or implied by, these forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to, such factors, including risk factors, discussed in the Company’s Registration Statement on Form SB-2, as amended on Form S-1, See www.sec.gov. Except as required by the Federal Securities law, the Company does not undertake any obligation to release publicly any revisions to any forward-looking statements to reflect.
The company has no obligation to update these forward-looking statements.
Frank Colapinto to Head New Division
Press Release Source: Eternal Image, Inc. On Wednesday March 10, 2010, 9:15 am
FARMINGTON HILLS, Mich., March 10, 2010 (GLOBE NEWSWIRE) — Eternal Image, Inc. (the “Company”) (OTCBB:ETNL – News), a public company engaged in the design, manufacturing and marketing of officially licensed funerary products such as caskets, urns, monuments and vaults, today announced that it has successfully retained the services of Mr. Frank Colapinto. He will assume the position of President of the Company’s forthcoming new division as previously reported in a press release dated March 4, 2010.
“Eternal Image could not have found a more qualified individual to spearhead our new division that will handle the manufacturing and marketing of our ancillary products,” said Nick Popravsky, VP Sales & Marketing, Eternal Image. “Frank has decades of experience in the gift industry and his manufacturing and sales contacts around the world will be a tremendous asset to our Company.”
Frank Colapinto is a past Senior Vice President and President of two major gift industry companies with sales in excess of $60 million. He has more than 35 years of global gift industry experience and has always been a fixture at most national gift product shows. His own personal sales averaged over $10 million per year, and his book of business includes 500 independent sales reps both nationally and worldwide.
“I am thrilled to be on board with Eternal Image, “said Frank Colapinto. “This Company has enormous potential for growth and I plan to develop the ancillary product division into a very profitable segment for the Company’s bottom line. Candles, register books, prayer cards and keepsakes–my plans for them all are global in scope and I will exponentially increase the availability of Eternal Image products to an international market.”
About Eternal Image
Eternal Image, incorporated in 2006, is headquartered in Farmington Hills, MI. The company is the first and only manufacturer and marketer of licensed brand image funerary products. Currently, the company offers urns and caskets that feature licensed images from Major League Baseball(TM), STAR TREK(R), Precious Moments(TM), the Vatican Observatory Foundation(R), and the Collegiate Licensing Company, as well as pet urns featuring the American Kennel Club(TM), and Cat Fanciers’(TM) Association. For more information about EI, visit www.eternalimage.net or call 1-888-6-CASKET.
SAFE HARBOR STATEMENT
Statements in this news release relating to plans, strategies, economic performance and trends, projections of results of specific activities or investments, and other statements that are not descriptions of historical facts may be forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1993 and Section 21E of the Securities Exchange Act of 1934.
Forward-looking information is inherently subject to risks and uncertainties, and actual results could differ materially from those currently anticipated due to a number of factors, which include but are not limited to risk factors inherent in doing business. Forward-looking statements may be identified by terms such as “may”, “will,” “should,” “could,” “expects,” “plans,” “intends,” “anticipates,” “believes,” “estimates,” “predicts,” “forecasts,” “potential” or “continue” or similar terms or the negative of these terms.
Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, levels of activity, performance or achievements. These forward-looking statements are based on information currently available to the Company and are subject to a number of risks, uncertainties, and other factors that could cause the Company’s actual results, performance, prospects, and opportunities to differ materially from those expressed in, or implied by, these forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to, such factors, including risk factors, discussed in the Company’s Registration Statement on Form SB-2, as amended on Form S-1, See www.sec.gov. Except as required by the Federal Securities law, the Company does not undertake any obligation to release publicly any revisions to any forward-looking statements to reflect.
The company has no obligation to update these forward-looking statements.
Monday, March 8, 2010
CEO of Eternal Image BUYS shares of company
On March 5, 2010, Clint Mytych made a small purchase of shares of ETNL as reported in a Form 4 filed with the SEC. You can view the Form 4 HERE.
Sunday, March 7, 2010
Eternal Image Inc. (ETNL) Annotated Video Chart
Our annotated video chart of ETNL can be viewed on Screencast at:
OTC Showcase Newsletter Vol. 1 Released - ETNL
If you haven't already subscribed to the newsletter, it can be viewed online at:
Website open for business
OTC Showcase (OTCS) has opened a week early. We are excited about the potential as the reviews has been nothing shy of outstanding so far. We are distinguishing ourselves from competitors in our industry by being extremely selective as to which companies we will provide market awareness. ETNL (Eternal Image, Inc) is a company that we hold in high regard and will be spotlighting from here forward. More information on ETNL will be provided here and on our other social media sites including:
Twitter: http://twitter.com/OTCShowcase
Please subscribe to us at those sites and at our website: http://www.otcshowcase.com/ where you can subscribe to our weekly newsletter to stay in tune with all the corporate information on the companies that have earned a "Spotlight" at OTCS.
Also be sure to check out our partner website: http://pincherplays.com/. Pincher Plays is an incredible stock market forum that is brand new in this format and doing extremely well. The members there work together on finding stock charts and plays to reap consistent stock market gains. You can begin your education on technical analysis there and we highly recommend grabbing the "Understanding Pincher Plays" video tutorial. This can be purchased at the special price of $59.99 (the least expensive stock charting video on the market) at: http://pincherplays.com/pinchervideopage.html. The video is 90 minutes packed with information about the pincher play and the basics of technical analysis. The testimonials from people have been astonishing.
Thank you and be sure to bookmark us!!
Subscribe to:
Posts (Atom)